Avalon GloboCare 
Welcome,         Profile    Billing    Logout  
  Products    Diseases   Products    Trials    News 
23 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
SENL-B19 / SenlangBio
NCT03312205: CAR-T Cells for Relapsed or Refractory Haematopoietic and Lymphoid Malignancies

Recruiting
1/2
50
RoW
Autologous CAR-T cells
Hebei Senlang Biotechnology Inc., Ltd., Hebei Yanda Ludaopei Hospital, Beijing Lu Daopei Hospital
Leukemia, Lymphoma, Multiple Myeloma of Bone (Diagnosis)
08/19
08/23
CTR20221359: Phase I clinical study of Senl_B19 autologous T cell injection in the treatment of r/r B-ALL

Recruiting
1
18
China
SENL-B19 - SenlangBio
Hebei Senlang Biotechnology Co., Ltd.
Relapsed/refractory CD19-positive B-cell acute lymphoblastic leukemia
 
 
Senl 1904A / SenlangBio
NCT03840317: Senl_1904A and Senl_1904B Chimeric Antigen Receptor (CAR) T-Cell in the Treatment of r/ r Acute B Lymphocytic Leukemia

Active, not recruiting
1
20
RoW
Autologous CD19-targeting CAR T cells
Hebei Senlang Biotechnology Inc., Ltd., Hebei Yanda Ludaopei Hospital
Acute Lymphocytic Leukemia
09/21
01/22
Senl 1904B / SenlangBio
NCT04447547: Clinical Trial of SL1904B CAR-T Cells for Relapsed or Refractory Non-Hodgkin Lymphoma

Recruiting
N/A
20
RoW
CD19 CAR-T
Hebei Senlang Biotechnology Inc., Ltd., Beijing Ludaopei Hospital, Hebei Yanda Ludaopei Hospital
Non-hodgkin's Lymphoma
08/22
12/22
NCT04546893: Safety and Efficacy Study of SL1904B CAR-T Cells for Relapsed or Refractory B-Cell Acute Lymphocyte Leukemia

Recruiting
N/A
20
RoW
CD19 CAR-T
Hebei Senlang Biotechnology Inc., Ltd., Hebei Yanda Ludaopei Hospital, Beijing Ludaopei Hospital
B-ALL
09/22
12/22
SL22P CAR-T cells / SenlangBio
NCT04556669: Anti-PD-L1 Armored Anti-CD22 CAR-T/CAR-TILs Targeting Patients With Solid Tumors

Recruiting
1
30
RoW
Autologous aPD-L1 armored anti-CD22 CAR T cells
Hebei Senlang Biotechnology Inc., Ltd.
Solid Tumor, Adult, Cervical Cancer, Sarcoma, NSCLC
08/23
08/25
senl_BCMA / SenlangBio
NCT04626752: CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma

Recruiting
1
50
RoW
BCMA CAR-T, senl_BCMA, Fludarabine, flu, Cyclophosphamide, ctx
Hebei Senlang Biotechnology Inc., Ltd.
Relapsed or Refractory Multiple Myeloma
03/23
03/23
NCT04447573: Immunotherapy With BCMA CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma

Recruiting
N/A
20
RoW
BCMA CAR-T
Hebei Senlang Biotechnology Inc., Ltd., Beijing Ludaopei Hospital, Hebei Yanda Ludaopei Hospital
Multiple Myeloma
08/22
12/22
NCT05618041: The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies

Recruiting
N/A
50
RoW
CAR-T Autologous T cell injection, CD19 CAR-T, CD20 CAR-T, BCMA CAR-T
Hebei Senlang Biotechnology Inc., Ltd., Hebei Taihe Chunyu Biotechnology Co., Ltd
Acute Lymphoblastic Leukemia, Lymphoma, Multiple Myeloma
09/27
12/27
Senl-h19 / SenlangBio
NCT04792593: Senl-h19 CAR-T Cell Injection in the Treatment of Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia

Recruiting
N/A
15
RoW
Senl-h19 CAR-T, CD19 CAR-T
Hebei Senlang Biotechnology Inc., Ltd.
B-ALL
12/21
02/22
SENL101 / SenlangBio
NCT06136364: CD7 CAR-T in Adults With Relapsed or Refractory T-LBL/ALL Clinical Study

Recruiting
1
9
RoW
CAR-T
Hebei Senlang Biotechnology Inc., Ltd.
T-lymphoblastic Lymphoma, T-ALL
08/24
08/38
NCT05398614: SENL101 Autologous T Cell Injection in Adults With Relapsed or Refractory CD7+ Hematolymphoid Malignancies

Recruiting
1
18
RoW
SENL101
Hebei Senlang Biotechnology Inc., Ltd.
T-ALL, Lymphoma, T-Cell
12/23
06/24
NCT04928105: Senl-T7 CAR-T Cells for Treatment of Relapsed or Refractory CD7+ Lymphoma

Recruiting
N/A
100
RoW
Senl-T7
Hebei Senlang Biotechnology Inc., Ltd.
Lymphoma, T-Cell
01/23
03/23
NCT04916860: Clinical Study of SenL-T7 CAR T Cells in the Treatment of Relapsed and Refractory CD7+ T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma

Active, not recruiting
N/A
100
RoW
Senl-T7
Hebei Senlang Biotechnology Inc., Ltd.
SenL-T7 CAR T Cells for CD7+ T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma
01/23
03/23
NCT04938115: Cell Therapy for CD7 Positive Acute Myeloid Leukemia or Mixed Lineage Leukemia

Completed
N/A
50
RoW
CD7 CART
Hebei Senlang Biotechnology Inc., Ltd.
Leukemia, T Cell
05/23
10/23
NCT05626400: Clinical Study of Senl-T7 CAR T Cells in the Treatment of Relapsed and Refractory CD7+ Acute T-ALL/T-LBL

Recruiting
N/A
100
RoW
Senl-T7
Hebei Senlang Biotechnology Inc., Ltd.
T-cell Acute Lymphoblastic Leukemia/Lymphoma
10/27
12/27
Senl_H19x22P / SenlangBio
NCT04626765: CAR-T for Children With Relapsed and Refractory Acute Lymphoblastic Leukemia

Recruiting
1
50
RoW
CD19 CAR-T, Senl_19, CD22 CAR-T, Senl_22, CD 19+22, Senl_19+22, Fludarabine, flu, Cyclophosphamide, ctx
Hebei Senlang Biotechnology Inc., Ltd., The Second Hospital of Hebei Medical University
Childhood Acute Lymphoblastic Leukemia
03/23
05/23
NCT04626739: CAR-T Cells in Treating Patients With Relapsed or Refractory NHL

Recruiting
1
100
RoW
CD19 CAR-T, Senl_19, CD22 CAR-T, Senl_22, CD19+CD22 CAR-T, Senl_19+22, Fludarabine, flu, Cyclophosphamide, ctx
Hebei Senlang Biotechnology Inc., Ltd.
Refractory Indolent Adult Non-Hodgkin Lymphoma
03/23
03/23
NCT04626726: Adult B-ALL Treated by CART Cell Bridging Allogeneic Hematopoietic Stem Cell Transplantation

Recruiting
1
50
RoW
CD19 CAR-T, Senl_19, CD22 CAR-T, Senl_22, CD19+CD22 CAR-T, Senl_19+22, Fludarabine, fiu, Cyclophosphamide, ctx
Hebei Senlang Biotechnology Inc., Ltd.
Adult B Acute Lymphoblastic Leukemia
05/23
05/23
NCT05206071: Clinical Study of SL19+22 CAR-T Cells for Relapsed or Refractory Non-Hodgkin Lymphoma

Recruiting
N/A
100
RoW
CD19+22 CAR-T cells, CD19+22 CAR-T
Hebei Senlang Biotechnology Inc., Ltd.
Non-hodgkin's Lymphoma
12/23
12/23
Anti-EphA2 CAR-T therapy / SenlangBio
NCT03423992: Personalized Chimeric Antigen Receptor T Cell Immunotherapy for Patients With Recurrent Malignant Gliomas

Recruiting
1
100
RoW
chimeric antigen receptor T cells
Xuanwu Hospital, Beijing, Beijing Mario Biotech Company, Hebei Senlang BIotech Company, Beijing HuiNengAn Biotech Company
Glioma, Malignant Glioma of Brain, Recurrence Tumor
01/23
01/23
autologous tumor-infiltrating lymphocyte / SenlangBio
NCT05333588: The Safety Study of Autologous TILs Therapy for Patients With Glioblastoma Multiforme.

Recruiting
1
20
RoW
Tumor Infiltrating Lymphocytes (TIL), TILs
Hebei Senlang Biotechnology Inc., Ltd.
Glioblastoma Multiforme, Adult
02/24
02/25
Senl_22 / SenlangBio
NCT04546906: Safety and Efficacy Study of CD22 CAR-T Cells for Relapsed or Refractory Acute Lymphoblastic Leukemia

Recruiting
N/A
20
RoW
CD22 CAR-T
Hebei Senlang Biotechnology Inc., Ltd.
B-ALL
09/22
12/22
Senl_005 / SenlangBio
No trials found
SENL102 / SenlangBio
No trials found
SENL301 / SenlangBio
No trials found
AVA-101 / Avalon GloboCare, Arbele
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
SENL-B19 / SenlangBio
NCT03312205: CAR-T Cells for Relapsed or Refractory Haematopoietic and Lymphoid Malignancies

Recruiting
1/2
50
RoW
Autologous CAR-T cells
Hebei Senlang Biotechnology Inc., Ltd., Hebei Yanda Ludaopei Hospital, Beijing Lu Daopei Hospital
Leukemia, Lymphoma, Multiple Myeloma of Bone (Diagnosis)
08/19
08/23
CTR20221359: Phase I clinical study of Senl_B19 autologous T cell injection in the treatment of r/r B-ALL

Recruiting
1
18
China
SENL-B19 - SenlangBio
Hebei Senlang Biotechnology Co., Ltd.
Relapsed/refractory CD19-positive B-cell acute lymphoblastic leukemia
 
 
Senl 1904A / SenlangBio
NCT03840317: Senl_1904A and Senl_1904B Chimeric Antigen Receptor (CAR) T-Cell in the Treatment of r/ r Acute B Lymphocytic Leukemia

Active, not recruiting
1
20
RoW
Autologous CD19-targeting CAR T cells
Hebei Senlang Biotechnology Inc., Ltd., Hebei Yanda Ludaopei Hospital
Acute Lymphocytic Leukemia
09/21
01/22
Senl 1904B / SenlangBio
NCT04447547: Clinical Trial of SL1904B CAR-T Cells for Relapsed or Refractory Non-Hodgkin Lymphoma

Recruiting
N/A
20
RoW
CD19 CAR-T
Hebei Senlang Biotechnology Inc., Ltd., Beijing Ludaopei Hospital, Hebei Yanda Ludaopei Hospital
Non-hodgkin's Lymphoma
08/22
12/22
NCT04546893: Safety and Efficacy Study of SL1904B CAR-T Cells for Relapsed or Refractory B-Cell Acute Lymphocyte Leukemia

Recruiting
N/A
20
RoW
CD19 CAR-T
Hebei Senlang Biotechnology Inc., Ltd., Hebei Yanda Ludaopei Hospital, Beijing Ludaopei Hospital
B-ALL
09/22
12/22
SL22P CAR-T cells / SenlangBio
NCT04556669: Anti-PD-L1 Armored Anti-CD22 CAR-T/CAR-TILs Targeting Patients With Solid Tumors

Recruiting
1
30
RoW
Autologous aPD-L1 armored anti-CD22 CAR T cells
Hebei Senlang Biotechnology Inc., Ltd.
Solid Tumor, Adult, Cervical Cancer, Sarcoma, NSCLC
08/23
08/25
senl_BCMA / SenlangBio
NCT04626752: CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma

Recruiting
1
50
RoW
BCMA CAR-T, senl_BCMA, Fludarabine, flu, Cyclophosphamide, ctx
Hebei Senlang Biotechnology Inc., Ltd.
Relapsed or Refractory Multiple Myeloma
03/23
03/23
NCT04447573: Immunotherapy With BCMA CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma

Recruiting
N/A
20
RoW
BCMA CAR-T
Hebei Senlang Biotechnology Inc., Ltd., Beijing Ludaopei Hospital, Hebei Yanda Ludaopei Hospital
Multiple Myeloma
08/22
12/22
NCT05618041: The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies

Recruiting
N/A
50
RoW
CAR-T Autologous T cell injection, CD19 CAR-T, CD20 CAR-T, BCMA CAR-T
Hebei Senlang Biotechnology Inc., Ltd., Hebei Taihe Chunyu Biotechnology Co., Ltd
Acute Lymphoblastic Leukemia, Lymphoma, Multiple Myeloma
09/27
12/27
Senl-h19 / SenlangBio
NCT04792593: Senl-h19 CAR-T Cell Injection in the Treatment of Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia

Recruiting
N/A
15
RoW
Senl-h19 CAR-T, CD19 CAR-T
Hebei Senlang Biotechnology Inc., Ltd.
B-ALL
12/21
02/22
SENL101 / SenlangBio
NCT06136364: CD7 CAR-T in Adults With Relapsed or Refractory T-LBL/ALL Clinical Study

Recruiting
1
9
RoW
CAR-T
Hebei Senlang Biotechnology Inc., Ltd.
T-lymphoblastic Lymphoma, T-ALL
08/24
08/38
NCT05398614: SENL101 Autologous T Cell Injection in Adults With Relapsed or Refractory CD7+ Hematolymphoid Malignancies

Recruiting
1
18
RoW
SENL101
Hebei Senlang Biotechnology Inc., Ltd.
T-ALL, Lymphoma, T-Cell
12/23
06/24
NCT04928105: Senl-T7 CAR-T Cells for Treatment of Relapsed or Refractory CD7+ Lymphoma

Recruiting
N/A
100
RoW
Senl-T7
Hebei Senlang Biotechnology Inc., Ltd.
Lymphoma, T-Cell
01/23
03/23
NCT04916860: Clinical Study of SenL-T7 CAR T Cells in the Treatment of Relapsed and Refractory CD7+ T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma

Active, not recruiting
N/A
100
RoW
Senl-T7
Hebei Senlang Biotechnology Inc., Ltd.
SenL-T7 CAR T Cells for CD7+ T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma
01/23
03/23
NCT04938115: Cell Therapy for CD7 Positive Acute Myeloid Leukemia or Mixed Lineage Leukemia

Completed
N/A
50
RoW
CD7 CART
Hebei Senlang Biotechnology Inc., Ltd.
Leukemia, T Cell
05/23
10/23
NCT05626400: Clinical Study of Senl-T7 CAR T Cells in the Treatment of Relapsed and Refractory CD7+ Acute T-ALL/T-LBL

Recruiting
N/A
100
RoW
Senl-T7
Hebei Senlang Biotechnology Inc., Ltd.
T-cell Acute Lymphoblastic Leukemia/Lymphoma
10/27
12/27
Senl_H19x22P / SenlangBio
NCT04626765: CAR-T for Children With Relapsed and Refractory Acute Lymphoblastic Leukemia

Recruiting
1
50
RoW
CD19 CAR-T, Senl_19, CD22 CAR-T, Senl_22, CD 19+22, Senl_19+22, Fludarabine, flu, Cyclophosphamide, ctx
Hebei Senlang Biotechnology Inc., Ltd., The Second Hospital of Hebei Medical University
Childhood Acute Lymphoblastic Leukemia
03/23
05/23
NCT04626739: CAR-T Cells in Treating Patients With Relapsed or Refractory NHL

Recruiting
1
100
RoW
CD19 CAR-T, Senl_19, CD22 CAR-T, Senl_22, CD19+CD22 CAR-T, Senl_19+22, Fludarabine, flu, Cyclophosphamide, ctx
Hebei Senlang Biotechnology Inc., Ltd.
Refractory Indolent Adult Non-Hodgkin Lymphoma
03/23
03/23
NCT04626726: Adult B-ALL Treated by CART Cell Bridging Allogeneic Hematopoietic Stem Cell Transplantation

Recruiting
1
50
RoW
CD19 CAR-T, Senl_19, CD22 CAR-T, Senl_22, CD19+CD22 CAR-T, Senl_19+22, Fludarabine, fiu, Cyclophosphamide, ctx
Hebei Senlang Biotechnology Inc., Ltd.
Adult B Acute Lymphoblastic Leukemia
05/23
05/23
NCT05206071: Clinical Study of SL19+22 CAR-T Cells for Relapsed or Refractory Non-Hodgkin Lymphoma

Recruiting
N/A
100
RoW
CD19+22 CAR-T cells, CD19+22 CAR-T
Hebei Senlang Biotechnology Inc., Ltd.
Non-hodgkin's Lymphoma
12/23
12/23
Anti-EphA2 CAR-T therapy / SenlangBio
NCT03423992: Personalized Chimeric Antigen Receptor T Cell Immunotherapy for Patients With Recurrent Malignant Gliomas

Recruiting
1
100
RoW
chimeric antigen receptor T cells
Xuanwu Hospital, Beijing, Beijing Mario Biotech Company, Hebei Senlang BIotech Company, Beijing HuiNengAn Biotech Company
Glioma, Malignant Glioma of Brain, Recurrence Tumor
01/23
01/23
autologous tumor-infiltrating lymphocyte / SenlangBio
NCT05333588: The Safety Study of Autologous TILs Therapy for Patients With Glioblastoma Multiforme.

Recruiting
1
20
RoW
Tumor Infiltrating Lymphocytes (TIL), TILs
Hebei Senlang Biotechnology Inc., Ltd.
Glioblastoma Multiforme, Adult
02/24
02/25
Senl_22 / SenlangBio
NCT04546906: Safety and Efficacy Study of CD22 CAR-T Cells for Relapsed or Refractory Acute Lymphoblastic Leukemia

Recruiting
N/A
20
RoW
CD22 CAR-T
Hebei Senlang Biotechnology Inc., Ltd.
B-ALL
09/22
12/22
Senl_005 / SenlangBio
No trials found
SENL102 / SenlangBio
No trials found
SENL301 / SenlangBio
No trials found
AVA-101 / Avalon GloboCare, Arbele
No trials found

Download Options